Montanova Capital LLC cut its position in Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report) by 1.6% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,135,406 shares of the company’s stock after selling 18,090 shares during the quarter. Palvella Therapeutics makes up about 2.9% of Montanova Capital LLC’s investment portfolio, making the stock its 5th largest position. Montanova Capital LLC owned 0.08% of Palvella Therapeutics worth $173,513,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of PVLA. Northwestern Mutual Wealth Management Co. acquired a new position in Palvella Therapeutics during the 2nd quarter valued at about $35,000. Penn Capital Management Company LLC acquired a new stake in shares of Palvella Therapeutics in the second quarter valued at approximately $841,000. Hsbc Holdings PLC acquired a new stake in shares of Palvella Therapeutics in the second quarter valued at approximately $7,641,000. Wellington Management Group LLP raised its holdings in shares of Palvella Therapeutics by 4.6% during the second quarter. Wellington Management Group LLP now owns 35,594 shares of the company’s stock valued at $5,439,000 after buying an additional 1,554 shares during the last quarter. Finally, Archer Investment Corp bought a new stake in shares of Palvella Therapeutics during the second quarter valued at approximately $69,000. 40.11% of the stock is currently owned by institutional investors.
Insider Transactions at Palvella Therapeutics
In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at approximately $327,860.34. This trade represents a 66.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Stock Report on PVLA
Palvella Therapeutics Trading Up 1.7%
Shares of NASDAQ:PVLA opened at $152.59 on Tuesday. The company has a 50 day moving average of $146.69 and a 200-day moving average of $127.75. The firm has a market cap of $2.20 billion, a P/E ratio of -31.59 and a beta of -0.17. Palvella Therapeutics, Inc. has a twelve month low of $49.81 and a twelve month high of $161.38.
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Equities research analysts forecast that Palvella Therapeutics, Inc. will post -6.36 EPS for the current year.
Palvella Therapeutics Company Profile
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
Featured Articles
- Five stocks we like better than Palvella Therapeutics
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report).
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
